Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
LS301-IT 0.1 mg/kg
DRUG
2 trials
Sponsors
Integro Theranostics
Conditions
Breast Cancer
DCIS
Invasive Duct Carcinoma of Breast
Non Small Cell Lung Cancer (NSCLC)
Phase 1
LS301-IT in Partial Mastectomy and Sentinel Lymph Node Biopsy (SLNB) for DCIS or Stage I-II Primary Invasive Breast Cancer
Completed
NCT05900986
Integro Theranostics
Breast Cancer, DCIS, Invasive Duct Carcinoma of Breast
Start: 2023-07-14
End: 2026-05-06
Updated: 2026-05-20
Phase 2
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Recruiting
NCT07276789
Integro Theranostics
Non Small Cell Lung Cancer (NSCLC)
Start: 2025-12-08
End: 2026-09-01
Target: 35
Updated: 2026-04-20